The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Reducing adverse events from amivantamab with dexamethasone in NSCLC
Gilberto Lopes, MD, University of Miami, Miami, FL, comments on the findings of the Phase II SKIPPirr study (NCT05663866), which aimed to reduce infusion-related reactions (IRRs) in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) treated with amivantamab and lazertinib. Patients received dexamethasone, methotrexate, or montelukast, and only dexamethasone two days before infusion of amivantamab managed to successfully decrease adverse events. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
